Insider · CIK 0001810701
Maria Palasis
Files at LYRA (Lyra Therapeutics, Inc.), BBNX (Beta Bionics, Inc.). First filing Jul 14, 2025, latest Jan 8, 2026.
In brief
Maria Palasis files SEC Form 4 as CEO, president and director at LYRA (Lyra Therapeutics, Inc.), and also at BBNX (Beta Bionics, Inc.). Since Jul 14, 2025, Maria Palasis has reported 0 open-market buys worth $0 and 4 open-market sells worth $99k, the latest filed on Jan 8, 2026.
A track record needs three past buys with six months of prices behind them; Maria Palasis has 0, so none is measured yet.
The newest scored trade: sold $5,726 of LYRA on Jan 6, 2026, filed Jan 8, 2026, scored 13 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 3 sells worth $85k.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
LYRA: Lyra Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
BBNX: Beta Bionics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 13Weak | Lyra Therapeutics, Inc. | $5,726 1,702 shares | -0% | +17% from low-88% from high | |
| 21Weak | Beta Bionics, Inc. | $42k 1,406 shares | -14% | +204% from low-6% from high | |
| 14Weak | Beta Bionics, Inc. | $38k 1,406 shares | -13% | +180% from low0% from high | |
| 13Weak | Lyra Therapeutics, Inc. | $14k 1,565 shares | -0% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 27, 2026 | LYRA Lyra Therapeutics, Inc. | 1,895 0.11% of outstanding | $3,248 | Jan 27, 2026 | $5,725 |
| Jan 6, 2026 | LYRA Lyra Therapeutics, Inc. | 1,702 0.10% of outstanding | $5,725 | Jan 6, 2026 | $3,881 |
| Oct 31, 2025 | BBNX BETA BIONICS INC | 2,812 0.01% of outstanding | $75k | Oct 31, 2025 | none |
| Oct 14, 2025 | LYRA Lyra Therapeutics, Inc. | 537 0.03% of outstanding | $3,881 | Oct 14, 2025 | none |
| Jul 10, 2025 | LYRA Lyra Therapeutics, Inc. | 1,565 0.00% of outstanding | $14k | Jul 10, 2025 | none |
| Apr 9, 2025 | LYRA Lyra Therapeutics, Inc. | 39,567 0.06% of outstanding | $3,545 | Apr 9, 2025 | none |
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | BBNX Beta Bionics, Inc. | AGrant or award Common Stock | +16,965 | $0.00 | $0 | 29,397 | May 26, 2026 |
| Apr 1, 2026 | LYRA Lyra Therapeutics, Inc. | DDisposition to issuer Common Stock10b5-1 | -2,000 | $0.00 | $0 | 1,094,733 | Apr 3, 2026 |
| Jan 13, 2026 | BBNX Beta Bionics, Inc. | AGrant or award Common Stock | +3,997 | $0.00 | $0 | 12,432 | Jan 14, 2026 |
| Jan 6, 2026 | LYRA Lyra Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,702 | $3.36 | $5,726 | 1,096,733 | Jan 8, 2026 |
| Dec 1, 2025 | BBNX Beta Bionics, Inc. | SOpen-market sale Common Stock10b5-1 | -906 | $29.33 | $27k | 8,935 | Dec 2, 2025 |
| Dec 1, 2025 | BBNX Beta Bionics, Inc. | SOpen-market sale Common Stock10b5-1 | -500 | $29.96 | $15k | 8,435 | Dec 2, 2025 |
| Oct 31, 2025 | BBNX Beta Bionics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,287 | $26.86 | $35k | 9,960 | Nov 5, 2025 |
| Oct 31, 2025 | BBNX Beta Bionics, Inc. | SOpen-market sale Common Stock10b5-1 | -119 | $27.45 | $3,267 | 9,841 | Nov 5, 2025 |
| Oct 1, 2025 | LYRA Lyra Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +3,667 | $0.00 | $0 | 7,333 | Oct 3, 2025 |
| Jul 10, 2025 | LYRA Lyra Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,565 | $8.91 | $14k | 1,098,435 | Jul 14, 2025 |
| Mar 15, 2025 | BBNX Beta Bionics, Inc. | AGrant or award Common Stock | +11,247 | $0.00 | $0 | 11,247 | Mar 18, 2025 |
| Jan 31, 2025 | BBNX Beta Bionics, Inc. | AGrant or award Director Stock Option (right to buy)derivative | +9,137 | $0.00 | $0 | 9,137 | Feb 3, 2025 |
| Dec 9, 2024 | LYRA Lyra Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +183,333 | $0.00 | $0 | 183,333 | Dec 11, 2024 |
| Oct 16, 2024 | LYRA Lyra Therapeutics, Inc. | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Oct 18, 2024 |
Questions about Maria Palasis
Answered from the filings on this page, as of the latest one.
Is Maria Palasis buying or selling?
In the last 12 months Maria Palasis reported 0 open-market buys worth $0 and 3 open-market sells worth $85k on SEC Form 4; the latest was sold $5,726 of LYRA on Jan 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Maria Palasis's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Maria Palasis has 0.
Where does Maria Palasis file Form 4?
Maria Palasis has filed Form 4 at LYRA (Lyra Therapeutics, Inc.) as Principal Executive Officer; BBNX (Beta Bionics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.